Bowden Becomes Chief Scientific Officer at BDC

It is with great pleasure that we announce Dr. Charles Bowden has accepted the role of Chief Scientific Officer at Biomedical Development Corporation where he will oversee the ongoing development of the KIOS Bipolar expert system.

Dr. Bowden is clinical professor and former Chairman of Psychiatry at the University of Texas Health Science Center at San Antonio. He is an internationally respected authority on bipolar disorder and the only scientist to receive all three of the top U.S. awards for mood disorder research.  He was named by Thomas Reuter’s as one of the World’s 100 Most Influential Scientific Minds in Psychiatry or Psychology for 2014.

Dr. Bowden is currently concluding the 52-week randomized clinical trial of KIOS Bipolar under the National Institutes of Mental Health grant. To date, user feedback from the study has been positive about KIOS Bipolar. In April, you can read here what these bipolar users said after a year of testing the KIOS Bipolar program. In the interim, see what prior study participants have said after completing a 12-week trial.

As part of his new role as CSO, Dr. Bowden will serve as Principal Investigator on an upcoming clinical trial and beta test of the KIOS Bipolar system with select individuals on probation with the Bexar County Criminal Justice System. The study is funded by the Commonwealth of Kentucky and will involve approximately 20 bipolar individuals who are completing programs in the mental health courts and who will use the KIOS Bipolar system for 12 weeks. At the conclusion of this period, they will provide feedback on its ease of use and its effectiveness in improving their ability to self-manage their bipolar symptoms. The trial data will also be analyzed to determine if regular use of KIOS Bipolar correlates to improvement in the user’s clinical bipolar states.

We appreciate the interest, efforts and guidance we have received to date from Bexar County and the financial support of The Commonwealth of Kentucky. We collectively hope the KIOS Bipolar tool can empower probationers by honing their self-management and disease-management skills.

We are excited by all the progress here at KIOS Bipolar and look forward to ongoing success with Dr. Bowden as CSO.  Stay tuned to for updates on the product and our progress. We anticipate KIOS Bipolar to be available to the general public via online subscription this July, 2017 at

Share this post

© 2017 Biomedical Development Corporation. All rights reserved. Trademarks not belonging to BDC are the property of their respective companies. iPhone and iPad are registered trademarks of Apple Inc.

¹ Research reported in this publication was supported by the National Institute Of Mental Health of the National Institutes of Health under Award Number R42MH091997. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

² This technology was supported in part by an award from the Kentucky Cabinet for Economic Development, Office of Entrepreneurship, under the Grant Agreement KSTC-184-512-15-223 with the Kentucky Science and Technology Corporation